PREVIEW
Approval of several antiepileptic drugs since 1993 has implications for primary care physicians who are treating epileptic patients. How do these new agents differ from standard therapy? What advantages do they offer? The authors of this article take a comprehensive look at five new agents—felbamate, fosphenytoin, gabapentin, lamotrigine, and topiramate.